

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/N7F40E05FB7EN.html>

Date: July 2018

Pages: 73

Price: US\$ 3,500.00 (Single User License)

ID: N7F40E05FB7EN

Abstracts

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

SUMMARY

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Attention Deficit Hyperactivity Disorder (ADHD),

Bipolar Disorder (Manic Depression), Cognitive Disorders, Parkinson's Disease, Schizophrenia, Smoking Addiction, Traumatic Brain Injury, Chronic Cough, Chronic Pain, Cognitive Impairment, Complex Regional Pain Syndrome, Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Ischemic Stroke, Major Depressive Disorder, Neurodegenerative Diseases, Neuropathic Pain, Obesity, Pain and Post-Traumatic Stress Disorder (PTSD).

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7

(CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in
Therapeutics Development

Bionomics Ltd

Bristol-Myers Squibb Co

CoMentis Inc

Epigen Biosciences Inc

Johnson & Johnson

Merck & Co Inc

Neuro Bio Ltd

NeuroDerm Ltd

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
(nicotine + opipramol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-8168 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bradanicline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gln-1062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTS-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-39393406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

SKL-20540 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VQW-765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones

Featured News & Press Releases

May 23, 2018: Bionomics: Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation

Apr 11, 2018: Phase 2 Clinical Trial of BNC210 For Treatment of Post traumatic Stress Disorder Fully Recruited

Apr 06, 2018: Bionomics To Host KOL Meetings Focused On BNC210 And The Treatment Of PTSD In New York And London

Dec 19, 2017: Neurodyn Appoints Anthony J. Giovinazzo as Director and Executive Chairman

Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs

Sep 01, 2017: Bionomics BNC210 to Feature at the 30th ECNP Congress

Aug 21, 2017: Bionomics & MSD 5th Annual Neuroscience Symposium in October

Jul 21, 2017: Bionomics Presents at 13th Annual Bioshares Biotech Summit

Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data

May 18, 2017: Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention

Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment

Jan 09, 2017: Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase

Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP

Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bionomics Ltd, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by CoMentis Inc, H2 2018
Pipeline by Epigen Biosciences Inc, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Neuro Bio Ltd, H2 2018
Pipeline by NeuroDerm Ltd, H2 2018
Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018
Pipeline by Vanda Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Bionomics Ltd

Bristol-Myers Squibb Co

CoMentis Inc

Epigen Biosciences Inc

Johnson & Johnson

Merck & Co Inc

Neuro Bio Ltd

NeuroDerm Ltd

SK Biopharmaceuticals Co Ltd

Vanda Pharmaceuticals Inc

I would like to order

Product name: Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/N7F40E05FB7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N7F40E05FB7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970